Search

Your search keyword '"Emrich, H.M."' showing total 135 results
Start Over Author "Emrich, H.M."
135 results on '"Emrich, H.M."'

14. Sildenafil citrate (VIAGRA): analysis of preferred doses in a European, six-month, double-blind, placebo-controlled, flexible dose-escalation study in patients with erectile dysfunction. Multicentre Study Group

Author

Hartmann, U., Meuleman, E.J.H., Cuzin, B., Emrich, H.M., Declercq, G.A., Bailey, M.J., Maytom, M.C., Smith, M.D., and Osterloh, I.H.

Subjects
Modelvorming en verificatie van het erectiemechanisme, Modelling and verification of the mechanism of erection
Abstract

Item does not contain fulltext

Published
1999

26. Effects of Acamprosate on Memory in Healthy Young Subjects

Author

SCHNEIDER, U., WOHLFARTH, K., SCHULZE-BONHAGE, A., HAACKER, T., MULLER-VAHL, K.R., ZEDLER, M., BECKER, H., DENGLER, R., and EMRICH, H.M.

Subjects
Alcoholism -- Physiological aspects -- Research, Memory -- Physiological aspects -- Research -- Health aspects, Alcohol in the body -- Health aspects -- Physiological aspects -- Research, Alcohol metabolism -- Research -- Physiological aspects -- Health aspects, Health, Psychology and mental health, Physiological aspects, Research, Health aspects
Abstract

Objective: Several studies have shown acamprosate (calciumacetylhomotaurinate) to increase abstinence rates in weaned alcoholics. Chronic alcoholics often suffer from cognitive deficits. Since acamprosate appears to interact with N-methyl-D-aspartate (NMDA) receptors, a subclass of glutamate receptors playing an important role in learning and memory processes, this study was performed in order to investigate different cognitive functions during administration of acamprosate. Method: A randomized, double-blind, cross-over, placebo-controlled design, involving 12 healthy male volunteers was used. Acamprosate 2g daily per os or placebo were administered for 7 days respectively, with a wash-out interval of 21 days between phases. Mood and different memory functions (i.e., working memory, delayed recall, recognition tasks) were assessed. Results: It was shown that a dose of acamprosate 2g/day for 7 days may produce an impairment in delayed free recall. Recognition tasks, short term working memory and mood were not altered. Conclusions: The present study supports the hypothesis that acamprosate impairs memory functions. This is in keeping with the concept of acamprosate acting as NMDA receptor antagonist. The limitations of the study are discussed. (J. Stud. Alcohol 60: 172-175, 1999), Acamprosate constitutes the calcium salt of an acetylated form of homotaurine. Although it has been proven effective in several studies in reducing relapses into drinking, its exact mechanisms of action [...]

Published
1999

40. Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance--a pilot study.

Author

Seifert, J., Peters, E., Jahn, K., Metzner, C., Ohlmeier, M., Te Wildt, B., Emrich, H.M., and Schneider, U.

Subjects
ALCOHOL withdrawal syndrome treatment, MEMORY, CARBAMAZEPINE, DETOXIFICATION (Substance abuse treatment), NEUROPSYCHOLOGICAL tests, NEUROPSYCHOLOGY
Abstract

Although relatively little attention has been paid to the question how acute alcohol withdrawal might affect cognitive functions, this factor remains of particular interest because it influences psychotherapeutic treatment during detoxification. The clinical outcome and neuropsychological state of 37 inpatients with alcohol withdrawal was investigated in a randomized single-blind approach. Two different medical strategies [chlormethiazole (CMZ) vs. carbamazepine (CBZ)] in the treatment of inpatients with alcohol withdrawal syndrome were compared. Among comparable groups (related to gender, age, initial alcohol level, severity of abuses, severity of initial withdrawal symptoms such as tremor, perspiration, psychomotor agitation, hallucinations, orientation, intelligence, patient demographics), CBZ is just as potent as CMZ in therapy of withdrawal symptoms (circulatory function, vegetative function, psychomotor activity). Patients in both groups showed initial impairments in some neuropsychological tests (d2, Zahlen-Verbundings test, Beck Depression Inventory, Anxiety Sensitivity Index) with significant improvement during detoxification. Additionally, CBZtreated patients showed significantly better verbal memory performance during the first days of treatment. Without any addictive potential, CBZ therapy could be very supportive in alcohol detoxification. In addition a higher verbal memory performance state could be favourable for a psychotherapeutic approach. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results